PATENT CLAIM ANALYSIS

Application Number: 16159269
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["424", "134100"]

Abstract:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.

Claim (Index 23):
The formulation of  claim 21 , wherein the first VEGF receptor is human Flt1 and the second VEGF receptor is selected from the group consisting of human Flk1 and the human Flt4.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 97.0
- Lexical Diversity: 1.22222
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15879294', '15095606', '15151776', '11818463', '12560885']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8601806309340655
- 35 USC 102 Novelty (BERT): 0.6032989920218036
- Combined Prediction Score: 0.8344924670428393
- Mean Citation Score: 526.7239000000002
- Max Citation Score: 542.981
- Similarity Product: 490.9639798674584

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test